The lifecycle of extracellular vesicles (EVs) is poorly understood and their potential as non-invasive biomarkers and therapy targets is a growing area of interest. This research can perfectly be integrated with the high need for novel biomarkers and therapy targets for prostate cancer. Any relief in the burden of this disease will have major impact on the huge socio-economic problems for patients, families, caregivers and society. In proEVLifeCycle, we aim to unravel the mysteries of EV biogenesis, homing and uptake to explain how EVs operate in disease processes, their heterogeneity, their molecular complexity, the biological functions they drive, their local and systemic dissemination and how these may be manipulated.

10 early stage researchers are joining us in achieving these objectives through a PhD research project. Our international consortium is composed of 8 academic institutions and 2 companies that offer them an excellent and innovative scientific training through research towards a PhD degree and extensive opportunities for mobility and patient-facing experiences, with the support of 11 partner organisations. Our ESRs will jointly clarify the lifecycle of EVs and identify novel biomarkers and therapy targets for one of the most frequently occurring cancers using state-of-the-art model systems, imaging and profiling tools, and systems biology.